Document is current

Any future updates will be listed below

Efficacy and safety of abemaciclib plus endocrine therapy versus endocrine therapy alone in HR + and HER2-negative breast cancer; a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1007/s10549-025-07836-x

Published Online: 2025-12-12

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark